Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary/Abstract
For over 2 decades the University of Zimbabwe-University of California, San Francisco Clinical Trials Unit (UZ-
UCSF CTU) has continuously conducted high quality Phase I-IV clinical trials, utilizing experienced teams of
multidisciplinary, cross-trained investigators, and research staff across the multi-Network CTU. The CTU is a
center of excellence in the prevention and control of HIV/AIDS and has contributed to the global understanding
of HIV epidemiology and pathogenesis, policy, and standards of care. In the current funding cycle, the CTU
enrolled over 6,700 participants in 48 clinical trials across all 5 NIH-funded Networks (ACTG, IMPAACT,
HPTN, HVTN, MTN) at 7 Clinical Research Sites (CRSs), generating 138 scientific articles and informing
Zimbabwe’s health policy. The CTU has innovated to overcome operational challenges occasioned by the
political and economic environment in Zimbabwe. The CTU proposes to continue to develop its scientifically
rigorous and well-managed CTU to support the scientific agendas of the 4 proposed Networks (ACTG,
IMPAACT, HPTN, HVTN), train the next generation of research leaders in Zimbabwe, and contribute to the
control and prevention of HIV and TB in Zimbabwe and globally, with 4 Specific Aims: Specific Aim 1. Lead
robust contributions to the research agendas of the ACTG, IMPAACT, HPTN, HVTN Networks; a) Continue to
advance evaluation of novel and durable systemic ARV-based therapeutic and preventive strategies for: (i)
control of HIV replication in the absence of ART; (ii) control of communicable and non-communicable
comorbidities; and (iii) prevention of HIV in Key Populations, including adolescent girls and young women, men
who have sex with men, and female sex workers by evaluating novel PrEP drug delivery systems; b) Continue
evaluation of novel preventative and therapeutic vaccine candidates and broadly neutralizing antibodies for
HIV/TB control among children, adolescents, and adults; c) Implement integrated strategies to evaluate socio-
behavioral, biomedical, and structural interventions for HIV prevention among high-risk Key Populations while
optimizing treatment outcomes among children, adolescents, and adults living with HIV; d) Investigate new
product acceptability, uptake, and adherence using mixed methods to assess the effectiveness of novel
approaches, including Multi-Purpose Prevention Technologies; Specific Aim 2. Intensify community
engagement at all stages of research and evolve Community Advisory Board membership to represent,
mobilize, and empower Key Populations, in support of the UNAIDS 95-95-95 targets; Specific Aim 3. Maintain
and adapt our CTU’s efficient and sophisticated centralized research infrastructures across the CRSs and the
Laboratory, Pharmacy, Community, Regulatory, Quality Management, Administration and Finance
Departments to drive compliance and ensure efficient execution of trials; and Specific Aim 4. Fortify the CTU’s
role as a local, regional, and global knowledge hub with investments in training and mentorship for the next
generation of scientific and community-based leaders.
Public Health Relevance Statement
Project Narrative
This award will support the CTU to continue its third decade of high impact, globally relevant HIV and TB
prevention and therapeutic research, aligned with Network scientific objectives, and in support of Zimbabwe
Ministry of Health policy goals, and designed to advance progress toward UNAIDS 95-95-95 targets. The CTU
will help to develop future research aims and disseminate lessons learned to inform local, regional, and
international efforts and best practices aimed at changing the trajectory of the HIV pandemic, and ultimately,
result in its control.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS clinical trial groupAIDS preventionAdherenceAdolescentAdultAnti-Retroviral AgentsAwardBreast FeedingCaliforniaCaringChildClinical TrialsClinical Trials UnitCollaborationsCommunitiesComplexDrug Delivery SystemsEconomicsEffectivenessEnrollmentEnsureEnvironmentEpidemiologyEvaluationFemale AdolescentsFundingGoalsHIVHIV Vaccine Trials NetworkHIV prevention trialHIV prevention trials networkHIV/AIDSHIV/TBHealth PolicyInternationalInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInterventionInvestmentsLaboratoriesLeadLearningMentorsMentorshipMethodologyMethodsMicrobicide Trials NetworkMissionOutcomeParticipantPathogenesisPerformancePharmacy facilityPhasePoliciesPoliticsPopulationPreventionPrevention ResearchPrevention approachPrevention strategyPreventive vaccineResearchResearch InfrastructureResearch PriorityRoleSan FranciscoSocial BehaviorTechnologyTherapeuticTherapeutic ResearchTrainingTreatment outcomeUnited States National Institutes of HealthUniversitiesWomanWorkZimbabweantiretroviral therapycis-femaleclinical research sitecommunity advisory boardcommunity engagementcomorbiditydesigneffectiveness evaluationempowermentexperiencefemale sex workerfortificationhigh riskhigh risk populationimprovedinnovationinvestigator trainingknowledge hubmen who have sex with menmultidisciplinaryneutralizing antibodynext generationnovelnovel strategiespandemic diseasepre-exposure prophylaxispregnantsocialtherapeutic vaccinetreatment optimizationuptakevaccine candidatevaccine trialyoung woman
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-March-2007
Project End Date
30-November-2027
Budget Start Date
01-December-2023
Budget End Date
30-November-2024
Project Funding Information for 2024
Total Funding
$3,668,011
Direct Costs
$3,440,460
Indirect Costs
$384,533
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$3,668,011
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI069436-18
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI069436-18
Patents
No Patents information available for 5UM1AI069436-18
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI069436-18
Clinical Studies
No Clinical Studies information available for 5UM1AI069436-18
News and More
Related News Releases
No news release information available for 5UM1AI069436-18
History
No Historical information available for 5UM1AI069436-18
Similar Projects
No Similar Projects information available for 5UM1AI069436-18